 3. Progression or intolerance after treatment with at least imatinib 400 mg and 600800 mgd then sunitinib at either 50mgd on a 4w6w schedule or 37.5mgd continuous dosing. Intolerance is defined as documented grade 3 or higher toxicity requiring treatment interruption as documented in patient record. 